FDA Approves Donanemab for Early Alzheimer's

Once-monthly donanemab is"the first and only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed, which can result in lower treatment costs and fewer infusions," Eli Lilly said in a statement announcing approval.

"This approval marks another step forward in evolving the standard of care for people living with Alzheimer's disease that will ultimately include an arsenal of novel treatments, providing much needed hope to the Alzheimer's community," Howard Fillit, MD, co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation , said in the Eli Lilly statement.

In the overall population of patients receiving donanemab, 17% completed treatment at 6 months, 47% at 12 months, and 69% at 18 months on the basis of an assessment of amyloid levels via an amyloid PET.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA approves new Alzheimer's treatment, donanemab from Eli LillyFDA approval of the new Alzheimer's treatment, which will be branded as Kisunla, follows years of setbacks.
Source: CBSNews - 🏆 87. / 68 Read more »

FDA approves Alzheimer’s drug donanemab after months of delayThe agency determined that the potential of slowing the devastating disease in patients with mild cognitive impairment outweigh the risks of brain bleeds.
Source: washingtonpost - 🏆 95. / 72 Read more »

High Confidence Alzheimer's Drug Donanemab Will Get FDA Panel NodAn FDA advisory committee will meet June 10 to offer its opinion on whether the agency should greenlight donanemab for Alzheimer's disease.
Source: Medscape - 🏆 386. / 55 Read more »

Donanemab for Alzheimer's Gets Unanimous Thumbs Up From FDA PanelAn 11-member advisory panel to the US Food and Drug Administration unanimously endorsed the anti-amyloid donanemab for early Alzheimer's disease.
Source: Medscape - 🏆 386. / 55 Read more »